Waldenström macroglobulinemia: my way

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis

(2012) J. R. Mikhael et al.   BLOOD

The Impact of Advanced Age According to IPSSWM Cut-Off on the Outcome of Symptomatic and Asymptomatic Waldenström's Macroglobulinemia at Diagnosis

(2012) F Ricci et al.   Clinical Lymphoma Myeloma & Leukemia

Pathogenesis and Morbidity of Autoantibody Syndromes in Waldenstrom's Macroglobulinemia

(2012) Marvin J. Stone   Clinical Lymphoma Myeloma & Leukemia

IgM Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Waldenström's Macroglobulinemia (SWM)

(2012) Robert A. Kyle et al.   Clinical Lymphoma Myeloma & Leukemia

IgM Amyloidosis: Clinical Features in Therapeutic Outcomes

(2012) Morie A. Gertz et al.   Clinical Lymphoma Myeloma & Leukemia

High-risk clonal evolution in chronic B-lymphocytic leukemia: single-center interphase fluorescence in situ hybridization study and review of the literature

(2012) Ann Janssens et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Follicular lymphoma: 2011 update on diagnosis and management

(2011) Arnold Freedman   AMERICAN JOURNAL OF HEMATOLOGY

No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years

(2011) Efstathios Kastritis et al.   AMERICAN JOURNAL OF HEMATOLOGY

Evidence-based focused review of management of hyperviscosity syndrome

(2011) M. J. Stone et al.   BLOOD

A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma

(2011) Meaghan L. Khan et al.   BRITISH JOURNAL OF HAEMATOLOGY

Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia

(2011) Alessandra Tedeschi et al.   CANCER

Temporal and geographic variations of Waldenstrom macroglobulinemia incidence

(2011) Haijun Wang et al.   CANCER

From Myeloma Precursor Disease to Multiple Myeloma: New Diagnostic Concepts and Opportunities for Early Intervention

(2011) Ola Landgren et al.   CLINICAL CANCER RESEARCH

Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites

(2011) A J Greenberg et al.   LEUKEMIA

Mantle cell lymphoma: recent insights into pathogenesis, clinical variability, and new diagnostic markers

(2011) Birgitta Sander   SEMINARS IN DIAGNOSTIC PATHOLOGY

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia

(2010) Irene M. Ghobrial et al.   AMERICAN JOURNAL OF HEMATOLOGY

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma

(2010) C. B. Reeder et al.   BLOOD

Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia

(2010) Agathoclis Agathocleous et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia

(2010) Irene M. Ghobrial et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia

(2010) Irene M. Ghobrial et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab and Subcutaneous 2-Chloro-2′-Deoxyadenosine Combination Treatment for Patients With Waldenström Macroglobulinemia: Clinical and Biologic Results of a Phase II Multicenter Study

(2010) Daniele Laszlo et al.   JOURNAL OF CLINICAL ONCOLOGY

High-Dose Therapy and Autologous Stem-Cell Transplantation in Waldenström Macroglobulinemia: The Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

(2010) Charalampia Kyriakou et al.   JOURNAL OF CLINICAL ONCOLOGY

Allogeneic Stem-Cell Transplantation in Patients With Waldenström Macroglobulinemia: Report From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

(2010) Charalampia Kyriakou et al.   JOURNAL OF CLINICAL ONCOLOGY

Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)

(2010) Efstathios Kastritis et al.   LEUKEMIA RESEARCH

Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines

(2010) Stephen M. Ansell et al.   MAYO CLINIC PROCEEDINGS

Advances in the Diagnosis, Classification, Risk Stratification, and Management of Monoclonal Gammopathy of Undetermined Significance: Implications for Recategorizing Disease Entities in the Presence of Evolving Scientific Evidence

(2010) S. Vincent Rajkumar et al.   MAYO CLINIC PROCEEDINGS

Oncogenically active MYD88 mutations in human lymphoma

(2010) Vu N. Ngo et al.   NATURE

International prognostic scoring system for Waldenstrom macroglobulinemia

(2009) P. Morel et al.   BLOOD

Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial

(2009) Morie A. Gertz et al.   BRITISH JOURNAL OF HAEMATOLOGY

Immunoglobulin M ‘Flare’ after rituximab-associated acute tubular necrosis in Waldenström’s macroglobulinemia

(2009) Hassane Izzedine et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Thalidomide and rituximab in Waldenstrom macroglobulinemia

(2008) S. P. Treon et al.   BLOOD

Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003

(2008) M. V. Dhodapkar et al.   BLOOD

Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia

(2008) S. P. Treon et al.   BLOOD

Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia

(2008) S. P. Treon et al.   CLINICAL CANCER RESEARCH